PharmacyCodes



IRINOTECAN, CPT-11 en es it fr

IRINOTECAN, CPT-11 Brand names, IRINOTECAN, CPT-11 Analogs

IRINOTECAN, CPT-11 Brand Names Mixture

  • No information avaliable

IRINOTECAN, CPT-11 Chemical_Formula

C33H38N4O6

IRINOTECAN, CPT-11 RX_link

http://www.rxlist.com/cgi/generic2/irinot.htm

IRINOTECAN, CPT-11 fda sheet

IRINOTECAN,_CPT-11 FDA

IRINOTECAN, CPT-11 msds (material safety sheet)

IRINOTECAN,_CPT-11 MSDS

IRINOTECAN, CPT-11 Synthesis Reference

T. Miyasaka et al., U.S. pat. 4,604,463 (1985, 1986 both to Yakult Honsha)

IRINOTECAN, CPT-11 Molecular Weight

586.678 g/mol

IRINOTECAN, CPT-11 Melting Point

222-223 oC

IRINOTECAN, CPT-11 H2O Solubility

Soluble

IRINOTECAN, CPT-11 State

Solid

IRINOTECAN, CPT-11 LogP

4.372

IRINOTECAN, CPT-11 Dosage Forms

Solution for IM injection

IRINOTECAN, CPT-11 Indication

For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin).

IRINOTECAN, CPT-11 Pharmacology

Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. Irinotecan is a derivative of camptothecin. Camptothecins interact specifically with the enzyme topoisomerase I which relieves torsional strain in DNA by inducing reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks. Current research suggests that the cytotoxicity of Irinotecan is due to double-strand DNA damage produced during DNA synthesis when replication enzymes interact with the ternary complex formed by topoisomerase I, DNA, and either Irinotecan or SN-38. Mammalian cells cannot efficiently repair these double-strand breaks. The precise contribution of SN-38 to the activity of Irinotecan in humans is not known. Irinotecan is cell cycle phase-specific (S-phase).

IRINOTECAN, CPT-11 Absorption

100%

IRINOTECAN, CPT-11 side effects and Toxicity

Gastrointestinal complications, such as nausea, vomiting, abdominal cramping, diarrhea, and infection.

IRINOTECAN, CPT-11 Patient Information

IRINOTECAN, CPT-11 Organisms Affected

Humans and other mammals